CSIMarket
 
Livanova Plc  (LIVN)
Other Ticker:  
 
 
Price: $50.6000 $-0.52 -1.017%
Day's High: $51.2 Week Perf: -3.8 %
Day's Low: $ 50.04 30 Day Perf: 3.79 %
Volume (M): 781 52 Wk High: $ 59.86
Volume (M$): $ 39,508 52 Wk Avg: $50.08
Open: $50.68 52 Wk Low: $41.45



 Market Capitalization (Millions $) 2,774
 Shares Outstanding (Millions) 55
 Employees 4,000
 Revenues (TTM) (Millions $) 1,153
 Net Income (TTM) (Millions $) 18
 Cash Flow (TTM) (Millions $) 62
 Capital Exp. (TTM) (Millions $) 35

Livanova Plc
Livanova Plc is a diversified medical technology company that is committed to improving patient outcomes and reducing the cost of healthcare in the areas of cardiovascular and neuromodulation treatment. The company was formed in 2015, as a result of a merger between Cyberonics Inc. and Sorin Group.

Headquartered in London, Livanova operates in over 100 countries worldwide, with its primary focus being on the development, manufacture, and marketing of medical devices used in the treatment of various heart and neurological conditions. It has over 3,500 employees working across its various manufacturing and research facilities in the United States, Europe, and Asia-Pacific.

Livanovaes Cardiovascular business segment offers a range of products that include heart-lung equipment, oxygenators, perfusion systems, cannulae, and devices used in extracorporeal membrane oxygenation (ECMO) therapy. Its pioneering ECMO technology is widely recognized and used for treating life-threatening cardiopulmonary failure in neonatal and pediatric patients. The companyes implantable cardiac rhythm management products, including pacemakers, defibrillators, and cardiac resynchronization therapy devices, are designed to manage cardiac arrhythmias and heart failure.

The Neuromodulation business segment of Livanova provides products for the treatment of patients with epilepsy, depression, chronic pain, and other neurological disorders. Its Vagus Nerve Stimulation (VNS) Therapy System is a revolutionary device that delivers electrical stimulation to the vagus nerve, offering relief to patients with epilepsy and depression who have not responded to traditional treatments. The segment also produces Deep Brain Stimulation (DBS) Systems, which can reduce symptoms of movement disorders such as Parkinsones disease.

Livanova Plc is dedicated to research and development, with a strong pipeline of new products and technological innovation. They continually invest in research and development and have a strong focus on profitability and growth. They have a strong corporate culture, and their core values include focusing on patients, working collaboratively, continuous improvement, and maintaining a high level of ethical conduct.

In conclusion, Livanova Plc is a global leader in the development and manufacture of medical technology that improves the lives of people with heart and neurological conditions. With a dedicated team, strong product pipeline, and a commitment to innovation, Livanova is well-positioned to grow in the medical device market for many years to come.


   Company Address: 20 Eastbourne Terrace London 0
   Company Phone Number: 203 325-0660   Stock Exchange / Ticker: NASDAQ LIVN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Livanova Plc

Livanova Plc Surges Ahead with $110.65 Million Tax Refund Boost

Livanova Plc, a leading company in the Medical Equipment & Supplies sector, has reported impressive financial results for the period closing on December 31, 2023. The company witnessed a significant increase in its income per share, which soared by an impressive 859.07% to $0.29 per share. Furthermore, its revenue experienced a boost of 12.832% to reach $310.15 million, compared to the previous year.
Compared to its competitors in the Medical Equipment & Supplies sector, Livanova Plc's revenue growth was even more remarkable. In the fourth quarter of 2023, most corporations in the sector experienced a 7.86% increase in revenue relative to the same period a year ago. However, Livanova Plc outperformed its contemporaries by achieving a higher revenue growth rate.

Livanova Plc

Livanova Plc's Impressive Revenue Growth Makes for a Rewarding Reporting Season in Q3 2023

Interpreting Livanova Plc's recent financial results, it is evident that the company has experienced both positive and negative developments. While the company's revenue increased by an impressive 13.142% to $285.80 million in the September 30, 2023 report compared to the previous year's corresponding reporting season, it was disappointing to see a loss of $-0.14 shortfall per share.
However, it is worth noting that Livanova Plc's revenue growth in the third quarter of 2023 aligns favorably with its counterparts in the Medical Equipment & Supplies sector. The sector as a whole saw a 0.80% increase in top-line performance during the same period. In the previous reporting season, Livanova Plc experienced a decrease in revenue by -2.749% from $293.88 million, and the income per share also declined from $0.02 per share.

Livanova Plc

Livanova Plc's Earnings Plunge in Q2 2023 Despite Substantial Revenue Growth



Livanova Plc, a global medical technology company, recently released its second quarter financial report for 2023. The report revealed a sharp decline in income, while revenue showed substantial growth compared to the same quarter of the previous year. This article will provide an overview and analysis of Livanova Plc's financial performance during this period, as well as contextualize it within the company's current stock market performance.
Financial Results in Q2 2023:
Livanova Plc experienced a significant decline in its bottom-line as income fell sharply by -93.33% to $0.02 per share. However, revenue increased by 15.633% to $293.88 million from the same quarter a year before.
This decline in income was also evident when compared to the previous quarter, with earnings per share (EPS) plummeting by -85.71% from $0.14 to $0.02 per share. Nevertheless, revenue showed growth of 11.565% from $263.42 million.

Livanova Plc

The 9.678%, surge in revenue was very solid at in the financial first quarter of 2023

Livanova Plc is a company that has been making significant strides in the healthcare industry. Its first quarter financial report for 2023 showed remarkable growth both in terms of revenue and earnings per share (EPS). The company reported EPS growth of 133.33% to $0.14, which is a significant improvement from the prior year quarter. Revenue also increased by 9.678% to $263.42 million, compared to $240.18 million in the prior year quarter.
One of the highlights of the report was the significant increase in net income, which stood at $7.370 million. This represented a 146.24% increase from net earnings of $2.993 million reported in the financial first quarter of 2023 a year ago. This growth is noteworthy as it shows that the company is on a path towards profitability and financial stability.






 

Livanova Plc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com